Speech-Language Pathologists in Teutopolis, IL Accepting Medicare

6 Speech-Language Pathologists found. Showing 1 - 6

Mrs. Natasha Renee Ruholl, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 16136 E 1485th Ave, Teutopolis, IL 62467 Phone: 217-343-1617    Fax: 833-799-0369

Mrs. Patricai Ann Crawford Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 15561 N 1700th St, Teutopolis, IL 62467 Phone: 217-857-6644

Mrs. Erin Hardiek, M.S. CCC- SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 609 W Southern Row, Teutopolis, IL 62467 Phone: 217-246-3226

Kari Mcmanaway Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 309 E Main St, Teutopolis, IL 62467 Phone: 217-857-3232

Vicky Simmons Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 309 E Main St, Teutopolis, IL 62467 Phone: 217-857-3232

Lisa Jane Uthell, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 16800 N 1650th St, Teutopolis, IL 62467 Phone: 217-857-1120    Fax: 217-857-1120

News Archive

Physios to get prescribing powers

Physiotherapists and podiatrists are set to gain independent prescribing powers from 2014, under proposals unveiled by the Department of Health this week.

Genetic variation cues social anxiety in monkeys and humans

A genetic variation involving the brain chemical serotonin has been found to shape the social behavior of rhesus macaque monkeys, which could provide researchers with a new model for studying autism, social anxiety and schizophrenia.

Mercy Medical Center announces installation of premium Resona 7 ultrasound machines

Mercy Medical Center, a nationally recognized medical facility, has announced the installation of five premium Resona 7 ultrasound machines from Mindray for the hospital's Vascular Center, Paul R. Lucas, M.D., FACS, RPVI, Director, The Vascular Center at Mercy has announced.

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.

Read more Medical News

› Verified 3 days ago